Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak.

Published in: Infection & chemotherapy (2022)

Considering that high proportion of vaccinated patients in the Delta-predominant group, this finding suggests the uncertainty whether the effect of regdanvimab is maintained even during the Delta-predominant period. It is hence necessary to continuously monitor the effectiveness of regdanvimab as new SARS-CoV-2 variants emerge.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
ejection fraction
chronic kidney disease
randomized controlled trial
respiratory syndrome coronavirus
peritoneal dialysis
prognostic factors
gene expression